SABS

2.8103.44%
AK

Alexandra Kropotova

Independent Director

Dr. Alexandra Kropotova, M.D. M.B.A. is Executive VP & Chief Medical Officer at SAB Biotherapeutics, Inc. since June 2022. Dr. Kropotova joined the SAB Biotherapeutics, Inc. in June 2022. Dr. Kropotova serves as an Independent Director at iBio, Inc. since October 14, 2020. Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs. Since 2016, she has served as Vice President, Global Specialty R&D, Respiratory & Inflammation Therapeutic Area at Teva Pharmaceuticals, where she led the design and execution of global clinical development programs, the majority of which are biologic candidates for pulmonary, chronic inflammatory or autoimmune indications. Prior to joining Teva from 2007 to 2016, Dr. Kropotova served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno-Inflammation, Global R&D; and Senior Medical Director, Respiratory, Allergy & Anti-Infectives. Prior to joining Sanofi, she also served in various roles at Pfizer Inc. from 2002 to 2007, most recently as Director and Head of Global Clinical Respiratory and Analgesics. Dr. Kropotova received her Master of Business Administration Degree from Ohio University Graduate School of Business in Athens, Ohio; and her Medical Degree in Internal Medicine from the Vladivostok State Medical University, Vladivostok, Russia.

Positions